-
Something wrong with this record ?
Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2
J. Do Carmo Silva, S. Vesely, H. Luksanova, R. Prusa, M. Babjuk
Language English Country Netherlands
Document type Journal Article
NLK
Directory of Open Access Journals
from 2017
ROAD: Directory of Open Access Scholarly Resources
from 1987
PubMed
34486998
DOI
10.3233/tub-211509
Knihovny.cz E-resources
- MeSH
- Early Detection of Cancer MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local blood diagnosis genetics MeSH
- Biomarkers, Tumor blood MeSH
- Prostatic Neoplasms blood diagnosis genetics surgery MeSH
- Nomograms MeSH
- Postoperative Period MeSH
- Prostate pathology surgery MeSH
- Prostatectomy MeSH
- Prostate-Specific Antigen blood MeSH
- Protein Isoforms blood genetics MeSH
- Aged MeSH
- Neoplasm Grading MeSH
- Tissue Kallikreins blood MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: The role of isoforms of prostate specific antigen (PSA) and other kallikrein-related markers in early detection of biochemical recurrence (BCR) after radical prostatectomy (RP) is not well known and serum PSA is currently used in preoperative risk nomograms. OBJECTIVE: The aim of this research was to study pre- and early postoperative levels of important PSA isoforms and human kallikrein-2 to determine their ability to predict BCR and identify disease persistence (DP). METHODS: This study included 128 consecutive patients who underwent RP for clinically localized prostate cancer. PSA, fPSA, %fPSA, [-2]proPSA, PHI and hK2 were measured preoperatively, at 1 and 3 months after RP. We determined the ability of these markers to predict BCR and identify DP. RESULTS: The DP and BCR rate were 11.7%and 20.3%respectively and the median follow up was 64 months (range 3-76 months). Preoperatively, the independent predictors of BCR were PSA (p-value 0.029), [-2]proPSA (p-value 0.002) and PHI (p-value 0.0003). Post-RP, PSA was the single marker correlating with BCR, both at one (p-value 0.0047) and 3 months (p-value 0.0004). PSA, fPSA, [-2]proPSA and PHI significantly correlated to DP at 1 and 3 months post-RP (p-value < 0.05), although PSA had the most significant existing correlation (p-value < 0.0001). CONCLUSIONS: [-2]proPSA and PHI are preoperative predictors of BCR and DP that outperform the currently used serum PSA. At the early postoperative period there is no additional benefit of the other markers tested.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026317
- 003
- CZ-PrNML
- 005
- 20211026133010.0
- 007
- ta
- 008
- 211013s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3233/TUB-211509 $2 doi
- 035 __
- $a (PubMed)34486998
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Do Carmo Silva, Joana $u Department of Urology, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czech Republic
- 245 10
- $a Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2 / $c J. Do Carmo Silva, S. Vesely, H. Luksanova, R. Prusa, M. Babjuk
- 520 9_
- $a BACKGROUND: The role of isoforms of prostate specific antigen (PSA) and other kallikrein-related markers in early detection of biochemical recurrence (BCR) after radical prostatectomy (RP) is not well known and serum PSA is currently used in preoperative risk nomograms. OBJECTIVE: The aim of this research was to study pre- and early postoperative levels of important PSA isoforms and human kallikrein-2 to determine their ability to predict BCR and identify disease persistence (DP). METHODS: This study included 128 consecutive patients who underwent RP for clinically localized prostate cancer. PSA, fPSA, %fPSA, [-2]proPSA, PHI and hK2 were measured preoperatively, at 1 and 3 months after RP. We determined the ability of these markers to predict BCR and identify DP. RESULTS: The DP and BCR rate were 11.7%and 20.3%respectively and the median follow up was 64 months (range 3-76 months). Preoperatively, the independent predictors of BCR were PSA (p-value 0.029), [-2]proPSA (p-value 0.002) and PHI (p-value 0.0003). Post-RP, PSA was the single marker correlating with BCR, both at one (p-value 0.0047) and 3 months (p-value 0.0004). PSA, fPSA, [-2]proPSA and PHI significantly correlated to DP at 1 and 3 months post-RP (p-value < 0.05), although PSA had the most significant existing correlation (p-value < 0.0001). CONCLUSIONS: [-2]proPSA and PHI are preoperative predictors of BCR and DP that outperform the currently used serum PSA. At the early postoperative period there is no additional benefit of the other markers tested.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 650 _2
- $a časná detekce nádoru $7 D055088
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a lokální recidiva nádoru $x krev $x diagnóza $x genetika $7 D009364
- 650 _2
- $a nomogramy $7 D049451
- 650 _2
- $a pooperační období $7 D011184
- 650 _2
- $a prostata $x patologie $x chirurgie $7 D011467
- 650 _2
- $a prostatický specifický antigen $x krev $7 D017430
- 650 _2
- $a prostatektomie $7 D011468
- 650 _2
- $a nádory prostaty $x krev $x diagnóza $x genetika $x chirurgie $7 D011471
- 650 _2
- $a protein - isoformy $x krev $x genetika $7 D020033
- 650 _2
- $a tkáňové kalikreiny $x krev $7 D020840
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vesely, Stepan $u Department of Urology, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Luksanova, Hana $u Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Prusa, Richard $u Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Babjuk, Marko $u Department of Urology, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czech Republic $u Department of Urology, Medical University of Vienna, Austria
- 773 0_
- $w MED00008757 $t Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine $x 1423-0380 $g Roč. 43, č. 1 (2021), s. 197-207
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34486998 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133016 $b ABA008
- 999 __
- $a ok $b bmc $g 1715133 $s 1146824
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 43 $c 1 $d 197-207 $e - $i 1423-0380 $m Tumor biology $n Tumor Biol $x MED00008757
- LZP __
- $a Pubmed-20211013